Jack Nielsen - Mar 17, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Director
Signature
/s/ Christian Ulrich, Attorney-in-fact for Jack Bech Nielsen
Stock symbol
HRMY
Transactions as of
Mar 17, 2022
Transactions value $
-$810,373
Form type
4
Date filed
3/21/2022, 08:31 PM
Previous filing
Nov 12, 2021
Next filing
Mar 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Sale -$36.8K -735 -1.72% $50.05 42K Mar 17, 2022 See Footnote F1, F3, F4
transaction HRMY Common Stock Sale -$258K -5.16K -0.12% $50.05 4.3M Mar 17, 2022 See Footnote F2, F3, F4
transaction HRMY Common Stock Sale -$64.2K -1.28K -3.05% $50.10 40.7K Mar 18, 2022 See Footnote F1, F3, F5
transaction HRMY Common Stock Sale -$451K -9K -0.21% $50.10 4.29M Mar 18, 2022 See Footnote F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
F2 The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
F3 The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.
F4 The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5 The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.